- Home
- ALGS vs CLNN Comparison
ALGS vs CLNN Comparison
Compare ALGS & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- CLNN
- Stock Information
- Founded
- ALGS 2018
- CLNN 2012
- Country
- ALGS United States
- CLNN United States
- Employees
- ALGS 70
- CLNN N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- CLNN Health Care
- Exchange
- ALGS Nasdaq
- CLNN Nasdaq
- Market Cap
- ALGS 27.9M
- CLNN 26.1M
- IPO Year
- ALGS 2020
- CLNN N/A
- Fundamental
- Price
- ALGS $5.36
- CLNN $2.83
- Analyst Decision
- ALGS Strong Buy
- CLNN Strong Buy
- Analyst Count
- ALGS 1
- CLNN 5
- Target Price
- ALGS $70.00
- CLNN $50.20
- AVG Volume (30 Days)
- ALGS 184.5K
- CLNN 51.0K
- Earning Date
- ALGS 05-06-2025
- CLNN 05-07-2025
- Dividend Yield
- ALGS N/A
- CLNN N/A
- EPS Growth
- ALGS N/A
- CLNN N/A
- EPS
- ALGS N/A
- CLNN N/A
- Revenue
- ALGS $3,945,000.00
- CLNN $342,000.00
- Revenue This Year
- ALGS $580.86
- CLNN N/A
- Revenue Next Year
- ALGS N/A
- CLNN $2,066.67
- P/E Ratio
- ALGS N/A
- CLNN N/A
- Revenue Growth
- ALGS N/A
- CLNN N/A
- 52 Week Low
- ALGS $3.76
- CLNN $2.57
- 52 Week High
- ALGS $46.80
- CLNN $9.20
- Technical
- Relative Strength Index (RSI)
- ALGS 33.94
- CLNN 34.63
- Support Level
- ALGS $4.33
- CLNN $2.76
- Resistance Level
- ALGS $5.67
- CLNN $3.18
- Average True Range (ATR)
- ALGS 0.78
- CLNN 0.25
- MACD
- ALGS 0.43
- CLNN 0.05
- Stochastic Oscillator
- ALGS 49.61
- CLNN 38.33
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.